FSNUF
Fresenius SE & Co. KGaA
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
57.00
▲ 2.65 (4.88%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
54.35
Day high
57.00
Day low
57.00
Volume
165
Market cap
—
P/E (TTM)
—
52W range
51.89 – 58.16
Trailing performance
Returnvs SPY
1W
0.00%
+1.2%
1M
0.00%
-3.3%
3M
0.00%
-2.4%
6M
-2.77%
-14.7%
YTD
-2.77%
-14.7%
1Y
-3.55%
-23.7%
3Y
+68.53%
-6.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on FSNUF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $22.87B | $21.95B | $21.07B | $21.53B | +4.2% |
| Operating revenue | $22.87B | $21.95B | $21.07B | $21.53B | +4.2% |
| Cost of revenue | $17.18B | $16.32B | $16.10B | $16.13B | +5.3% |
| Gross profit | $5.69B | $5.64B | $4.97B | $5.40B | +1.0% |
| Research & development | $633.00M | $641.00M | $661.00M | $639.00M | -1.2% |
| Selling, general & admin | $2.88B | $2.89B | $3.03B | $3.09B | -0.2% |
| Total operating expense | $3.51B | $3.56B | $3.79B | $3.59B | -1.5% |
| Operating income | $2.18B | $2.07B | $1.18B | $1.81B | +5.2% |
| Net interest income | -$320.00M | -$429.00M | -$398.00M | -$215.00M | +25.4% |
| Pre-tax income | $2.19B | $1.68B | $773.00M | $1.60B | +30.1% |
| Tax provision | $582.00M | $530.00M | $485.00M | $375.00M | +9.8% |
| Net income | $1.26B | $471.00M | -$594.00M | $1.37B | +168.4% |
| Net income to common | $1.26B | $471.00M | -$594.00M | $1.37B | +168.4% |
| Basic EPS | 2.24 | 0.84 | -1.05 | 2.44 | +166.7% |
| Diluted EPS | 2.24 | 0.84 | -1.05 | 2.44 | +166.7% |
| EBIT | $2.63B | $2.23B | $1.29B | $1.94B | +17.9% |
| EBITDA | $3.75B | $3.47B | $2.69B | $3.10B | +8.1% |
| Basic shares | 563.24M | 563.24M | 563.24M | 561.26M | 0.0% |
| Diluted shares | 563.24M | 563.24M | 563.24M | 561.26M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $2.05B | $2.29B | $2.57B | -36.1% |
| Cash & short-term investments | $1.31B | $2.05B | $2.29B | $2.57B | -36.1% |
| Accounts receivable | $3.56B | $3.50B | $3.67B | $7.16B | +1.7% |
| Inventory | $2.61B | $2.57B | $2.52B | $4.83B | +1.5% |
| Total current assets | $11.03B | $11.45B | $12.52B | $18.28B | -3.7% |
| Property, plant & equipment | $9.72B | $9.89B | $10.78B | $18.84B | -1.7% |
| Goodwill & intangibles | $16.72B | $17.51B | $17.62B | $35.83B | -4.5% |
| Total assets | $41.40B | $43.55B | $45.28B | $76.40B | -4.9% |
| Total current liabilities | $8.38B | $9.01B | $9.33B | $13.66B | -6.9% |
| Current debt | $1.30B | $2.60B | $2.38B | $2.19B | -49.9% |
| Long-term debt | $9.22B | $9.48B | $11.46B | $18.99B | -2.7% |
| Total debt | $11.93B | $13.58B | $15.83B | $27.76B | -12.1% |
| Total liabilities | $21.63B | $23.26B | $25.63B | $44.18B | -7.0% |
| Shareholder equity | $19.10B | $19.54B | $19.00B | $20.41B | -2.2% |
| Working capital | $2.64B | $2.44B | $3.19B | $4.62B | +8.5% |
| Net tangible assets | $2.39B | $2.04B | $1.38B | -$15.41B | +17.3% |
| Shares issued | 563.24M | 563.24M | 563.24M | 563.24M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | $1.61B | $1.15B | $288.00M | $1.22B | — | +39.4% |
| Depreciation & amortisation | $1.12B | $1.24B | $1.40B | $1.16B | — | -9.6% |
| Change in working capital | $267.00M | $79.00M | $399.00M | -$257.00M | — | +238.0% |
| Operating cash flow | $2.57B | $2.45B | $4.46B | $4.20B | — | +5.2% |
| Capital expenditure | -$1.50B | -$1.06B | -$1.29B | -$1.19B | — | -41.2% |
| Investing cash flow | -$815.00M | -$510.00M | -$3.19B | -$2.61B | — | -59.8% |
| Share buybacks | — | — | — | — | $0 | — |
| Dividends paid | -$684.00M | — | -$551.00M | -$403.00M | -$1.07B | — |
| Financing cash flow | -$2.42B | -$2.18B | -$1.38B | -$1.60B | — | -11.0% |
| Free cash flow | $1.08B | $1.39B | $3.17B | $3.00B | — | -22.4% |
| End cash position | $1.58B | $2.28B | $2.56B | $2.75B | — | -30.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $5.95B | $5.82B | $6.16B | — | $5.65B | $5.71B | +2.2% |
| Operating revenue | $5.95B | $5.82B | $6.16B | — | $5.65B | $5.71B | +2.2% |
| Cost of revenue | $4.39B | $4.28B | $4.63B | — | $4.19B | $4.29B | +2.6% |
| Gross profit | $1.55B | $1.53B | $1.52B | — | $1.46B | $1.41B | +1.0% |
| Research & development | $167.00M | $163.00M | $170.00M | — | $164.00M | $140.00M | +2.5% |
| Selling, general & admin | $760.00M | $743.00M | $824.00M | — | $741.00M | $644.00M | +2.3% |
| Total operating expense | $918.00M | $933.00M | $1.06B | — | $899.00M | $725.00M | -1.6% |
| Operating income | $632.00M | $601.00M | $468.40M | — | $562.00M | $689.00M | +5.2% |
| Net interest income | -$80.00M | -$58.00M | -$66.00M | — | -$107.00M | -$93.00M | -37.9% |
| Pre-tax income | $535.00M | $577.00M | $607.00M | — | $493.00M | $614.00M | -7.3% |
| Tax provision | $136.00M | $132.00M | $180.00M | — | $147.00M | $141.00M | +3.0% |
| Net income | $382.00M | $435.00M | $361.00M | — | $330.00M | $229.00M | -12.2% |
| Net income to common | $382.00M | $435.00M | $361.00M | — | $330.00M | $229.00M | -12.2% |
| Basic EPS | 0.68 | 0.77 | — | — | 0.58 | 0.41 | -11.7% |
| Diluted EPS | 0.68 | 0.77 | — | — | 0.58 | 0.41 | -11.7% |
| EBIT | $632.00M | $601.00M | $920.00M | — | $562.00M | $689.00M | +5.2% |
| EBITDA | $902.00M | $874.00M | $1.23B | $740.00M | $830.00M | — | +3.2% |
| Basic shares | 561.76M | 563.24M | — | — | 568.97M | 563.24M | -0.3% |
| Diluted shares | 561.76M | 563.24M | — | — | 568.97M | 563.24M | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.28B | $2.06B | $1.31B | $1.23B | $2.39B | -37.9% |
| Cash & short-term investments | $1.41B | $3.95B | $1.31B | $1.39B | $2.53B | -64.2% |
| Accounts receivable | $4.36B | $3.96B | $3.56B | $3.80B | $3.75B | +10.1% |
| Inventory | $2.77B | $2.73B | $2.61B | $2.59B | $2.64B | +1.6% |
| Total current assets | $11.61B | $12.07B | $11.03B | $10.88B | $11.91B | -3.8% |
| Property, plant & equipment | $9.78B | $9.73B | $9.72B | $9.63B | $9.77B | +0.5% |
| Goodwill & intangibles | $16.75B | $16.76B | $16.72B | $16.83B | $17.25B | -0.1% |
| Total assets | $41.84B | $42.37B | $41.40B | $41.32B | $43.21B | -1.2% |
| Total current liabilities | $9.07B | $9.54B | $8.38B | $8.30B | $8.33B | -4.9% |
| Current debt | $1.69B | $2.19B | $1.30B | $2.09B | $2.06B | -22.9% |
| Long-term debt | $8.33B | $8.31B | $9.22B | $9.31B | $10.09B | +0.2% |
| Total debt | $11.42B | $11.90B | $11.93B | $12.85B | $13.63B | -4.1% |
| Total liabilities | $21.45B | $21.91B | $21.63B | $22.38B | $23.14B | -2.1% |
| Shareholder equity | $19.70B | $19.78B | $19.10B | $18.28B | $19.41B | -0.4% |
| Working capital | $2.54B | $2.53B | $2.64B | $2.58B | $3.58B | +0.5% |
| Net tangible assets | $2.95B | $3.02B | $2.39B | $1.45B | $2.16B | -2.3% |
| Shares issued | 563.24M | 563.24M | 563.24M | 563.24M | 563.24M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $398.00M | — | — | $360.00M | $346.00M | $473.00M | — |
| Depreciation & amortisation | $270.00M | $273.00M | $314.00M | $274.00M | $268.00M | — | -1.1% |
| Change in working capital | -$327.00M | -$298.00M | $778.00M | $171.00M | -$139.00M | — | -9.7% |
| Operating cash flow | $344.00M | $389.00M | $1.34B | — | $418.00M | $56.00M | -11.6% |
| Capital expenditure | -$241.00M | -$196.00M | -$725.00M | -$335.00M | -$234.00M | — | -23.0% |
| Investing cash flow | $41.00M | $29.00M | -$433.00M | — | -$167.00M | $59.00M | +41.4% |
| Dividends paid | — | — | $0 | — | -$560.00M | -$96.00M | — |
| Financing cash flow | -$1.17B | $45.00M | -$1.71B | — | -$1.40B | $26.00M | -2,708.9% |
| Free cash flow | $103.00M | $193.00M | $619.00M | $421.00M | $184.00M | — | -46.6% |
| End cash position | $1.28B | $2.06B | $1.58B | — | $1.23B | $2.39B | -37.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
54.35
+4.88% from price
SMA 20
54.35
0.00% from price
SMA 50
54.35
0.00% from price
SMA 100
54.35
+4.88% from price
SMA 200
54.80
-0.82% from price
EMA 12
54.35
+4.88% from price
EMA 26
54.35
+4.88% from price
EMA 50
54.36
+4.85% from price
RSI (14)
29.3
Oversold
MACD (12,26,9)
-0.00
Hist 0.00
ATR (14)
0.00
—
Realised vol 30D
0.0%
Annualised
Bollinger upper
54.35
20, 2σ
Bollinger lower
54.35
20, 2σ
50 / 200 cross
Death
54.35 vs 54.80
Trend bias
Below 200
-0.82%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
-0.14
Less volatile than market
Correlation to SPY
-0.11
Largely independent
Realised vol 30D
0.0%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-10.8%
Peak to trough
Max drawdown 5Y
-62.7%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Zacks · 13d ago
Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...
GuruFocus.com · 19d ago
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
Business Wire · 21d ago
Fresenius: Q2 Earnings Snapshot
Associated Press · 21d ago
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
Zacks · 21d ago
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Business Wire · 24d ago
Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run
Simply Wall St. · 25d ago
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
Zacks · 27d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.